Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Himisha Beltran, M.D.

Title
Institution
Department
Address
Phone

Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. P50CA272390 (BELTRAN, HIMISHA) Sep 1, 2023 - Aug 31, 2028
    NIH
    DF/HCC Prostate SPORE
    Role: Principal Investigator
  2. R01CA274963 (RICKMAN, DAVID S.) Jun 1, 2023 - May 31, 2028
    NIH
    "DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer"
    Role: Co-Principal Investigator
  3. R37CA241486 (BELTRAN, HIMISHA) Apr 15, 2020 - Mar 31, 2027
    NIH
    Molecular mechanisms underlying lineage plasticity in prostate cancer
    Role: Principal Investigator
  4. P50CA090381 (BELTRAN, HIMISHA) Apr 1, 2001 - Jun 30, 2019
    NIH
    DF/HCC SPORE in Prostate Cancer
    Role: Principal Investigator

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
Displaying 25 of 237 total Publications Show all
  1. Lozada JR, Elliott A, Evans MG, Wacker J, Storey KM, Egusa EA, Zorko NA, Kumar A, Crymes A, Heath EI, Carneiro BA, Soares HP, Cichocki F, Miller JS, Lou E, Beltran H, Antonarakis ES, Ryan CJ, Hwang JH. Expression Patterns of DLL3 Across Neuroendocrine and Non-Neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting. Cancer Res Commun. 2025 Jan 28. PMID: 39874041.
    Citations:
    Fields: NeoNeoplasms
  2. Yu EY, Rumble RB, Agarwal N, Cheng HH, Eggener SE, Bitting RL, Beltran H, Giri VN, Spratt D, Mahal B, Lu K, Crispino T, Trabulsi EJ. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. J Clin Oncol. 2025 Jan 09; JCO2402608. PMID: 39787437.
    Citations:
    Fields: NeoNeoplasms
  3. Shore N, Nielsen SM, Esplin ED, Antonarakis ES, Barata PC, Beer TM, Beltran H, Bryce A, Cookson MS, Crawford ED, Dorff TB, George DJ, Heath EI, Helfand BT, Hussain M, Mckay RR, Morgans AK, Morris MJ, Paller CJ, Ross AE, Sartor O, Shen J, Sieber P, Smith MR, Wise DR, Armstrong AJ. Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now. JCO Oncol Pract. 2024 Dec 19; OP2400626. PMID: 39700441.
    Citations:
    Fields: NeoNeoplasms
  4. McKay RR, Lang J, Beltran H. Clinical Implementation of Minimal Residual Disease Testing in Genitourinary Cancers: Bridging Promise and Practice. Eur Urol. 2024 Dec 13. PMID: 39674780.
    Citations:
    Fields: UroUrology
  5. Knutson TP, Luo B, Kobilka A, Lyman J, Guo S, Munro SA, Li Y, Heer R, Gaughan L, Morris MJ, Beltran H, Ryan CJ, Antonarakis ES, Armstrong AJ, Halabi S, Dehm SM. AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients. Nat Commun. 2024 Dec 11; 15(1):10648. PMID: 39663356; PMCID: PMC11634963.
    Citations:
    Fields: BioBiologySciScienceTranslation:CTClinical Trials
  6. Bryce AH, Agarwal N, Beltran H, Hussain MH, Sartor O, Shore N, Antonarakis ES, Armstrong AJ, Calais J, Carducci MA, Dorff TB, Efstathiou JA, Gleave M, Gomella LG, Higano C, Hope TA, Iagaru A, Morgans AK, Morris DS, Morris MJ, Petrylak DP, Reiter RE, Rettig MB, Ryan CJ, Sellinger SB, Spratt DE, Srinivas S, Tagawa ST, Taplin ME, Yu EY, Zhang T, McKay RR, Koo PJ, Crawford ED. Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. Cancer. 2025 Jan 01; 131(1):e35612. PMID: 39616467; PMCID: PMC11694557.
    Citations:
    Fields: NeoNeoplasms
  7. Haffner MC, Morris MJ, Ding CC, Sayar E, Mehra R, Robinson B, True LD, Gleave M, Lotan TL, Aggarwal R, Huang J, Loda M, Nelson PS, Rubin MA, Beltran H. Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies. Clin Cancer Res. 2024 Nov 26. PMID: 39589343.
    Citations: 1
    Fields: NeoNeoplasms
  8. Chatterjee SS, Linares JF, Cid-Diaz T, Duran A, Khan MIK, Osrodek M, Brady NJ, Reina-Campos M, Marzio A, Venkadakrishnan VB, Bakht MK, Khani F, Mosquera JM, Robinson BD, Moyer J, Elemento O, Hsieh AC, Goodrich DW, Rickman DS, Beltran H, Moscat J, Diaz-Meco MT. Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer. Nat Commun. 2024 Nov 20; 15(1):9755. PMID: 39567499; PMCID: PMC11579030.
    Citations:
    Fields: BioBiologySciScienceTranslation:HumansAnimalsCells
  9. Ravi P, Zhong C, Xie W, Kelly E, Whelpley B, Kuczmarski K, Beltran H, Kilbridge KL, King MT, McGregor BA, Morgans AK, Pomerantz M, Taplin ME, Tewari AK, Viswanathan SR, Wei XX, Anh Huynh M, Choudhury AD. Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer. Eur Urol Oncol. 2024 Nov 14. PMID: 39547900.
    Citations:
    Fields: NeoNeoplasmsUroUrology
  10. Jensen JL, Bobek O, Chan ICC, Miller BC, Hillman DW, Heller G, Druley T, Armstrong AJ, Morris MJ, Milowsky MI, Beltran H, Bolton KL, Coombs CC. Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201). Clin Cancer Res. 2024 Nov 01; 30(21):4910-4919. PMID: 39287426; PMCID: PMC11539927.
    Citations:
    Fields: NeoNeoplasmsTranslation:Humans
  11. Bakht MK, Beltran H. Aiming High: Prostate-specific Membrane Antigen Expression in Treatment-naïve Prostate Cancer. Eur Urol. 2024 Dec; 86(6):588-590. PMID: 39394012.
    Citations:
    Fields: UroUrology
  12. Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efstathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, Suzuki H, Taplin ME, Thellenberg-Karlsson C, Tilki D, Türkeri LN, Uemura H, Ürün Y, Vale CL, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2025 Feb; 87(2):157-216. PMID: 39394013.
    Citations: 2
    Fields: UroUrology
  13. Choi SH, Pan E, Elliott A, Beltran H, Panian J, Jamieson C, Bagrodia A, Rose B, Herchenhorn D, Heath E, Nabhan C, Antonarakis ES, McKay RR. Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer. Mol Cancer Res. 2024 10 02; 22(10):920-931. PMID: 38912907.
    Citations: 1
    Fields: CelCell BiologyMolMolecular BiologyNeoNeoplasms
  14. Dalal A, Clark-Garvey S, Gdowski A, Zhang S, Wobker SE, Rowe SP, Altun E, Beltran H, Milowsky MI. A Case of Rapidly Progressive De Novo Metastatic Small-Cell Neuroendocrine Prostate Cancer. Case Rep Oncol Med. 2024; 2024:7998149. PMID: 39318975; PMCID: PMC11421938.
    Citations:
  15. Wang Y, Scurll J, Rascón IA, Cui C, Ni Y, Shi AM, Gangadharannambiar P, Wang Y, Akamatsu S, Beltran H, Cox M, Crea F, Daugaard M, Dong X, Haffner M, He H, Jachetti E, Kyprianou N, Li B, Ong CE, Rickman DS, Sen T, Zhu HH, Zoubeidi A, Gleave ME. The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions. Epigenomics. 2024; 16(17):1129-1132. PMID: 39225130; PMCID: PMC11457638.
    Citations:
    Fields: GenGenetics
  16. German B, Alaiwi SA, Ho KL, Nanda JS, Fonseca MA, Burkhart DL, Sheahan AV, Bergom HE, Morel KL, Beltran H, Hwang JH, Freedman ML, Lawrenson K, Ellis L. MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer. Cancer Res Commun. 2024 09 01; 4(9):2295-2307. PMID: 39113611; PMCID: PMC11368174.
    Citations:
    Fields: NeoNeoplasms
  17. Venkadakrishnan VB, Presser AG, Singh R, Booker MA, Traphagen NA, Weng K, Voss NCE, Mahadevan NR, Mizuno K, Puca L, Idahor O, Ku SY, Bakht MK, Borah AA, Herbert ZT, Tolstorukov MY, Barbie DA, Rickman DS, Brown M, Beltran H. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Nat Commun. 2024 Aug 08; 15(1):6779. PMID: 39117665; PMCID: PMC11310309.
    Citations: 1
    Fields: BioBiologySciScienceTranslation:HumansAnimalsCells
  18. Meyer H, Sunkara R, Rothmann E, Shah A, Riaz I, Courtney KD, Armstrong AJ, Lippucci A, Naqvi SAA, Stanton ML, Beltran H, Bryce AH. The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate. Clin Genitourin Cancer. 2024 Oct; 22(5):102172. PMID: 39232269.
    Citations:
    Fields: NeoNeoplasmsUroUrology
  19. Ku SY, Wang Y, Garcia MM, Yamada Y, Mizuno K, Long MD, Rosario S, Chinnam M, Al Assaad M, Puca L, Kim MJ, Bakht MK, Venkadakrishnan VB, Robinson BD, Acosta AM, Wadosky KM, Mosquera JM, Goodrich DW, Beltran H. Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer. J Clin Invest. 2024 Jul 18; 134(17). PMID: 39024561; PMCID: PMC11364388.
    Citations: 3
    Fields: MedMedicine (General)Translation:HumansAnimalsCells
  20. Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol. 2025 01; 22(1):26-45. PMID: 38977769.
    Citations: 2
    Fields: UroUrology
  21. Basaria S, Taplin ME, McDonnell M, Simonson DC, Lin AP, Dufour AB, Habtemariam D, Nguyen PL, Ravi P, Kibel AS, Sweeney CJ, D'Amico AV, Roberts DA, Xu W, Wei XX, Sunkara R, Choudhury AD, Mantia C, Beltran H, Pomerantz M, Berchuck JE, Martin NE, Leeman JE, Mouw KW, Kilbridge KE, Bearup R, Kackley H, Kafel H, Huang G, Reid KF, Storer T, Braga-Basaria M, Travison TG. Insulin resistance during androgen deprivation therapy in men with prostate cancer. Cancer. 2024 Nov 01; 130(21):3671-3685. PMID: 38881266; PMCID: PMC11464184.
    Citations: 1
    Fields: NeoNeoplasmsTranslation:Humans
  22. Crawford ED, Bryce AH, Hussain MH, Agarwal N, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1. JU Open Plus. 2024 Apr; 2(4). PMID: 38774466; PMCID: PMC11108024.
    Citations: 1
  23. Bryce AH, Crawford ED, Agarwal N, Hussain MH, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. JU Open Plus. 2024 Apr; 2(4). PMID: 38774467; PMCID: PMC11107999.
    Citations: 1
  24. Venkadakrishnan VB, Presser AG, Singh R, Booker MA, Traphagen NA, Weng K, Voss NC, Mahadevan NR, Mizuno K, Puca L, Idahor O, Ku SY, Bakht MK, Borah AA, Herbert ZT, Tolstorukov MY, Barbie DA, Rickman DS, Brown M, Beltran H. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Res Sq. 2024 Mar 04. PMID: 38405800; PMCID: PMC10889062.
    Citations:
  25. Serritella AV, Beltran H, Lotan TL, VanderWeele DJ, Karzai F, Madan RA, Hussain M. Large Cell Neuroendocrine Prostate Cancer: Large Is Not Small. Oncologist. 2024 Mar 04; 29(3):185-189. PMID: 38206818; PMCID: PMC10911908.
    Citations: 2
    Fields: NeoNeoplasms
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contact@catalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resources@hms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappt@hms.harvard.edu.
Beltran's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (462)
Explore
_
Co-Authors (85)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
© 2025 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.